Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morabito

Showing results (301-310 of 307) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 307 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Frontiers in Endocrinology|May 13, 2024
Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlationSimona F Madeo, Luca Zagaroli, Sara Vandelli, et al.
ESMO Open|June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenarioL Cantini, G Mentrasti, G L Russo, et al.
ESMO Open|April 4, 2022
Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]L Cantini, G Mentrasti, G Lo Russo, et al.
Pageof 31

Showing results (301-310 of 307) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 307 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Frontiers in Endocrinology|May 13, 2024
Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlationSimona F Madeo, Luca Zagaroli, Sara Vandelli, et al.
ESMO Open|June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenarioL Cantini, G Mentrasti, G L Russo, et al.
ESMO Open|April 4, 2022
Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]L Cantini, G Mentrasti, G Lo Russo, et al.
Pageof 31